Vuagnat, P. (Perrine)

Filtering

20201

Settings

Author search.filters.isAuthorOfPublication.00180fdb-995c-4421-8918-56cde2a4967c

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Evidence of pseudoprogression in patients treated with PD1/ PDL1 antibodies across tumor types
    (2020) Massard, C. (Christophe); Martin-Romano, P. (Patricia); Vuagnat, P. (Perrine); Postel-Vinay, S. (Sophie); Castañon, E. (Eduardo); Marabelle, A. (Aurelien); Michot, J.M. (Jean Marie); Champiat, S. (Stéphane); Baldini, C. (Capucine); Ferté, C. (Charles); Hollebecque, A. (Antoine); Soria, J.C. (Jean-Charles); Varga, A. (Andrea); Ammari, S. (Samy)
    Background: PD(L)1 antibodies (anti-PD(L)-1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti-PD(L)-1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti-PD(L)-1. Methods: All consecutive patients (pts) enrolled in phase 1 trials with advanced solid tumors and lymphomas treated in phase I clinical trials evaluating monotherapy by anti-PD(L)-1 at Gustave Roussy were analyzed. We aimed to assess prevalence and outcome of PSPD across tumor types. We also intended to describe potential clinical and pathological factors associated with PSPD. Results: A total of 169 patients treated with anti-PD(L)-1 were included in the study. Most frequent tumor types included melanoma (n = 57) and non-small cell lung cancer (n = 19). At first tumor evaluation 77 patients (46%) presented with immune unconfirmed progressive disease. Six patients (8%) experienced PSPD: 2 patients with partial response; 4 patients with stable disease. Increase in target lesions in the first CT-scan was more frequently associated to PSPD (67% vs 33%; P = .04). Patients with a PSPD had a superior survival when compared to patients progressing (median OS: 10.7 months vs 8.7 months; P = .07). Conclusions: A small subset of PSPD patients may experience response after an initial progression. Assessment of the current strategy for immune-related response evaluations may require further attention.